

Medications Approved for the Treatment of Parkinson's Disease in the USA

Medications used to treat the motor symptoms of Parkinson's disease as of November 2024

Mechanism of action	Generic name	Trade name®	Potential side effects*
DOPA decarboxylase inhibitor/DA precursor	Carbidopa-levodopa	Sinemet	Nausea, dizziness, orthostatic hypotension, anxiety, dyskinesia, confusion, hallucinations, somnolence, peripheral neuropathy (acute and subacute forms more common with Duopa)
	Carbidopa-levodopa ER (extended release)		
	Carbidopa-levodopa (orally disintegrating)	Parcopa	
	Carbidopa-levodopa (extended-release capsules)	Crexont Rytary	
	Carbidopa-levodopa (enteral suspension)	Duopa	
	Foscarbidopa-foslevodopa (subcutaneous infusion)	Vyalev	
	Levodopa inhalation powder	Inbrija	
	Scored carbidopa-levodopa tablet	Dhivy	
COMT inhibitor, inhibits breakdown of levodopa	Entacapone	Comtan	Same as carbidopa-levodopa. In addition: diarrhea, discoloration of body fluids Tasmar can cause liver failure and requires monitoring of liver function
	Tolcapone	Tasmar	
	Opicapone	Ongentys	
DOPA decarboxylase inhibitor/DA precursor/COMT Inhibitor	Carbidopa-levodopa-entacapone	Stalevo	Same as carbidopa-levodopa and COMT inhibitor
DA agonist	Pramipexole	Mirapex	Nausea, dizziness, orthostatic hypotension, swelling of ankles, dyskinesia, hallucinations, confusion, somnolence, sleep attacks, impulse control disorders Neupro can lead to a skin reaction at the patch site
	Pramipexole (extended release)	Mirapex ER	
	Ropinirole	Requip	
	Ropinirole (extended release)	Requip XL	
	Apomorphine (injection)	Apokyn	
	Rotigotine (transdermal patch)	Neupro	

Medications Approved for the Treatment of Parkinson's Disease in the USA

Mechanism of action	Generic name	Trade name®	Potential side effects*
MAO-B inhibitor, inhibits breakdown of dopamine	Selegiline		Selegiline can cause insomnia
	Selegiline (orally disintegrating)	Zelapar	Dizziness, nausea, gastrointestinal upset, dyskinesia, hallucinations, confusion, headache
	Selegiline (transdermal patch)	Emsam	Note possible drug interactions between MAO-B inhibitors and other medications
	Rasagiline	Azilect	Safinamide exerts its effects through other mechanisms of action as well
	Safinamide	Xadago	
Adenosine 2A inhibitor	Istradefylline	Nourianz	Dyskinesia, dizziness, constipation, nausea, hallucinations, and insomnia
Mixed mechanisms, including NMDA antagonism	Amantadine		Hallucinations, leg swelling, dizziness, mottled skin (livedo reticularis), confusion, dry mouth and eyes, constipation, dizziness, orthostatic hypotension, somnolence Dose needs to be adjusted for kidney dysfunction
	Amantadine (extended release)	Gocovri	
Anticholinergic	Trihexyphenidyl		Dry mouth and eyes, constipation, urinary retention, memory impairment, confusion, depression, hallucinations
	Benzotropine	Cogentin	

Medications Approved for the Treatment of Parkinson's Disease in the USA

Medications used to treat the non-motor symptoms of Parkinson's disease as of November 2024**

Symptom treated	Mechanism of action	Generic name	Trade name®	Potential side effects*
Parkinson's disease psychosis	Inverse serotonin agonist	Pimavanserin	Nuplazid	Swelling of legs or arms, nausea, confusion, constipation QT interval prolongation (abnormal heart rhythm), increased risk of death in elderly patients with dementia-related psychosis
Neurogenic orthostatic hypotension	Norepinephrine precursor	Droxidopa	Northera	Headache, dizziness, nausea, high blood pressure (especially when lying down)
Parkinson's disease dementia	Acetylcholinesterase inhibitor	Rivastigmine	Exelon	Stomach upset, nausea, loss of appetite

COMT = catechol-O-methyltransferase

DA = dopamine

DOPA = dopamine

MAO-B = monoamine oxidase B

NMDA = N-methyl-D-aspartate


* Additional side effects may occur. Please discuss with your healthcare provider.

** The medications listed carry a specific indication for use in Parkinson's disease. Many other medications are used off-label for treatment of non-motor symptoms of Parkinson's disease.

Medications Approved for the Treatment of Parkinson's Disease in the USA



APDA SYMPTOM TRACKER



New & improved! An easier way to track your symptoms and manage your care.

Includes in-app Spanish language option.

Download the free APDA Symptom Tracker mobile app today.



National Headquarters

American Parkinson Disease Association
PO Box 61420
Staten Island, NY 10306

Telephone: 800-223-2732

Website: www.apdaparkinson.org

Email: apda@apdaparkinson.org

© 2024 American Parkinson Disease Association

The information contained in this fact sheet is written solely for the purpose of providing information to the reader, and is not intended as medical advice. This information should not be used for treatment purposes but rather for discussion with the patient's healthcare providers.

November 2024

Stay connected through our social media

